4D Molecular Therapeutics (FDMT) Other Non-Current Assets (2019 - 2026)

4D Molecular Therapeutics (FDMT) has reported Other Non-Current Assets for 8 consecutive years, with $9.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Assets rose 39.97% year-over-year to $9.9 million; the TTM figure through Mar 2026 stood at $9.9 million (up 39.97% YoY), while the FY2025 annual figure was $9.2 million, up 115.63% from the prior year.
• Other Non-Current Assets grew to $9.9 million in Q1 2026 per FDMT's latest filing, from $9.2 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $9.9 million in Q1 2026 and bottomed at $682000.0 in Q3 2023.
• Historically, Other Non-Current Assets has averaged $3.7 million across 5 years, with a median of $1.3 million in 2023.
• Annual changes were most pronounced in 2024 — Other Non-Current Assets slumped 38.81% — and 2025, when it soared 813.49%.
• 4D Molecular Therapeutics' Other Non-Current Assets stood at $1.1 million in 2022, then sank by 36.67% to $684000.0 in 2023, then soared by 522.95% to $4.3 million in 2024, then surged by 115.63% to $9.2 million in 2025, then increased by 7.29% to $9.9 million in 2026.
• Business Quant data shows FDMT's Other Non-Current Assets at $9.9 million in Q1 2026, $9.2 million in Q4 2025, and $9.4 million in Q3 2025.